<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">Liver metastasis</z:e> is the major obstacle for prolonging the survival of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH), a common drug for venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, has displayed beneficial effects in improving the survival of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients, though the mechanism remains unclear </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to investigate the effects of LMWH on <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> and its underlying molecular mechanism by targeting the interaction of the chemokine receptor CXCR4 and its ligand CXCL12 (formerly known as stromal cell-derived factor 1α, SDF-1α), as the CXCR4-CXCL12 axis has been shown to regulate the interaction of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells and stroma </plain></SENT>
<SENT sid="3" pm="."><plain>Experimental results revealed that LMWH (Enoxaparin, 3500-5500 Da) inhibited the CXCL12-stimulated proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and colony formation of human <z:hpo ids='HP_0003003'>colon cancer</z:hpo> HCT-116 cells that highly expressed CXCR4 </plain></SENT>
<SENT sid="4" pm="."><plain>Interestingly, LMWH or an anti-CXCR4 blocking antibody diminished the migrating and invading abilities of HCT116 cells stimulated by the recombinant CXCL12 protein or liver homogenates which contained endogenous CXCL12 protein </plain></SENT>
<SENT sid="5" pm="."><plain>Although LMWH did not significantly inhibit the growth of subcutaneous <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumors</z:e>, it significantly suppressed the formation of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> established by intrasplenic injection of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells in <z:mp ids='MP_0003815'>nude</z:mp> Balb/c mice and also downregulated the expression of CXCL12 in hepatic sinusoidal endothelial cells </plain></SENT>
<SENT sid="6" pm="."><plain>The results suggest that LMWH inhibits the formation of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastasis</z:e> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> by disrupting the interaction of CXCR4 and CXCL12, supporting that perioperative administration of LMWH may help to prevent the seeding and subsequent growth of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">hepatic metastases</z:e> of <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
</text></document>